EN | TR
E-ISSN: 3061-9947
Evaluation Of Demographic And Clinicopathological Characteristics Of Panreatic Adenocarcinoma Patients
PDF
Cite
Share
Request
Original Article
VOLUME: 49 ISSUE: 2
P: 91-101
2016

Evaluation Of Demographic And Clinicopathological Characteristics Of Panreatic Adenocarcinoma Patients

Acta Haematol Oncol Turc 2016;49(2):91-101
DOI: 10.5505/aot.2016.74946
Kaan Helvacı
Ümmügül Üyetürk
Özlem Sönmez
İbrahim Türker
Ülkü Yalçıntaş Arslan
1. Department Of Medical Oncology, Ankara Oncology Education And Research Hospital, Ankara, Turkey
2. Department Of Medical Oncology, Abant Izzet Baysal University Medical School, Bolu, Turkey
3. Department Of Medical Oncology, Yeditepe University Medical School, İstanbul, Turkey
4.
No information available.
No information available
Received Date: 2016-01-31T22:15:37
Accepted Date: 2016-06-02T11:02:18
PDF
Cite
Share
Request

Abstract

INTRODUCTION

In patients with pancreatic cancer twenty-six percent are locally advanced, 52% are metastatic and only 20-15% are surgically removable at the time of diagnosis (1). One-year overall survival rate of pancreatic cancer is 26% while 5 year overall survival rate is only 6% (2) The aim of this study is to analyze the clinicopathological features of the pancreatic adenocarcinoma patients who admitted to the Ankara Oncology Training and Research hospital.

METHODS

Total 193 pancreatic adenocarcinoma patients, including 72 women and 121 men, who were followed in Ankara Oncology Training and Research Hospital between dates 2007-2011, were evaluated retrospectively.

RESULTS

Twenty-six of the patients (13,5%) had undergone curative resection, 54 patients (28%) with locally advanced disease were unresectable, while 113 patients (58,5%) had metastatic disease. For the entire group (n=193), median survival time was 6 months. Older age (more than median “61”), low performance status (ECOG≥3), weight loss or abdominal pain on admission, high grade tumor, locally advanced or metastatic disease, metastasis other than peritonea or liver, multiple metastases at the time of diagnosis were the parameters which significantly affect survival negatively. After excluding the curatively operated patients, high levels of Ca 19-9 (higher than median value: 616) were associated with poor survival in patients with locally advanced or metastatic disease (p=0,021). Chemotherapy was significantly superior to best supportive care in the metastatic disease. Median overall survival in patients treated with chemotherapy versus best supportive care was 7 months (4,7 to 9,3) and 1 month (0,2 to 1,7) respectively (p<0,0001). There was no significant difference in overall survival with chemotherapy versus best supportive care in locally advanced unresectable group.

DISCUSSION AND CONCLUSION

As a result of demographic and clinical examination of patients, we generally reached similar conclusions with previous studies. Low median age of the disease may be associated with an earlier age of onset of smoking in Turkey. It would be wise to consider performance status and stage of the disease rather than the age of the patient while making treatment decisions.